{ "@graph": [    { "@id": "http://linked.opendata.cz/resource/ATC/C",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "CARDIOVASCULAR SYSTEM" , "@language" : "en" } ,        { "@value" : "Kardiovaskul\u00E1rn\u00ED syst\u00E9m" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "L\u00E9\u010Diva ovliv\u0148uj\u00EDc\u00ED renin-angiotenzinov\u00FD syst\u00E9m" , "@language" : "cs" } ,        { "@value" : "AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09C",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "ANGIOTENSIN II ANTAGONISTS, PLAIN" , "@language" : "en" } ,        { "@value" : "Antagonist\u00E9 angiotensinu II, samotn\u00ED" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09C" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09CA",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Antagonist\u00E9 angiotensinu II, samotn\u00ED" , "@language" : "cs" } ,        { "@value" : "Angiotensin II antagonists, plain" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09CA" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09CA01",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://www.w3.org/2004/02/skos/core#broaderTransitive" : [ "http://linked.opendata.cz/resource/ATC/C09" ,        "http://linked.opendata.cz/resource/ATC/C" ,        "http://linked.opendata.cz/resource/ATC/C09CA" ,        "http://linked.opendata.cz/resource/ATC/C09C" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Losartan" , "@language" : "cs" } ,        { "@value" : "Losartan" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09CA01" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0351838",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/Ingredient" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Losartan potassium" , "@language" : "en" } ,        { "@value" : "Losartan potassium" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPharmacologicalAction" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001326" ,        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001456" ,        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0456879" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/LOSARTAN-STADA-12-5-MG",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasActiveIngredient" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0351838" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "LOSARTAN STADA 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMedicinalProductPackaging" : [ "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106796" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106795" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0154345" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106797" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106794" ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001326",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Anti-arrhythmia agents" , "@language" : "en" } ,        { "@value" : "Antiarytmika" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001456",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Antihypertenz\u00EDva" , "@language" : "cs" } ,        { "@value" : "Antihypertensive agents" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0456879",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Blok\u00E1tory receptoru 1 pro angiotenzin ii" , "@language" : "cs" } ,        { "@value" : "Angiotensin ii type 1 receptor blockers" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0154345",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "LOSARTAN STADA 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC141639_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "10" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch, d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 \u2013 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u dosp\u011Bl\u00FDch pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-\tL\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba ACE inhibitory ji\u017E d\u00E1le nen\u00ED vhodn\u00E1 z\u00A0d\u016Fvodu inkompatibility, zejm\u00E9na ka\u0161le, \u010Di kontraindikac\u00ED. P\u0159ev\u00E1d\u011Bn\u00ED pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED jsou stabiln\u00ED na ACE inhibitoru, na losartan se nedoporu\u010Duje. \nPacienti by m\u011Bli m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40% a m\u011Bli by b\u00FDt stabilizov\u00E1ni na l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u dosp\u011Bl\u00FDch hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovanou na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 10X12,5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106797",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "LOSARTAN STADA 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC141639_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "98" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch, d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 \u2013 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u dosp\u011Bl\u00FDch pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-\tL\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba ACE inhibitory ji\u017E d\u00E1le nen\u00ED vhodn\u00E1 z\u00A0d\u016Fvodu inkompatibility, zejm\u00E9na ka\u0161le, \u010Di kontraindikac\u00ED. P\u0159ev\u00E1d\u011Bn\u00ED pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED jsou stabiln\u00ED na ACE inhibitoru, na losartan se nedoporu\u010Duje. \nPacienti by m\u011Bli m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40% a m\u011Bli by b\u00FDt stabilizov\u00E1ni na l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u dosp\u011Bl\u00FDch hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovanou na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 98X12,5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106794",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "LOSARTAN STADA 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC141639_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "28" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch, d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 \u2013 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u dosp\u011Bl\u00FDch pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-\tL\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba ACE inhibitory ji\u017E d\u00E1le nen\u00ED vhodn\u00E1 z\u00A0d\u016Fvodu inkompatibility, zejm\u00E9na ka\u0161le, \u010Di kontraindikac\u00ED. P\u0159ev\u00E1d\u011Bn\u00ED pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED jsou stabiln\u00ED na ACE inhibitoru, na losartan se nedoporu\u010Duje. \nPacienti by m\u011Bli m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40% a m\u011Bli by b\u00FDt stabilizov\u00E1ni na l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u dosp\u011Bl\u00FDch hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovanou na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 28X12,5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106796",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "LOSARTAN STADA 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC141639_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "60" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch, d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 \u2013 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u dosp\u011Bl\u00FDch pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-\tL\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba ACE inhibitory ji\u017E d\u00E1le nen\u00ED vhodn\u00E1 z\u00A0d\u016Fvodu inkompatibility, zejm\u00E9na ka\u0161le, \u010Di kontraindikac\u00ED. P\u0159ev\u00E1d\u011Bn\u00ED pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED jsou stabiln\u00ED na ACE inhibitoru, na losartan se nedoporu\u010Duje. \nPacienti by m\u011Bli m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40% a m\u011Bli by b\u00FDt stabilizov\u00E1ni na l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u dosp\u011Bl\u00FDch hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovanou na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 60X12,5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0106795",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "LOSARTAN STADA 12,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09CA01" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC141639_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "30" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "12.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "-\tL\u00E9\u010Dba esenci\u00E1ln\u00ED hypertenze u dosp\u011Bl\u00FDch, d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch ve v\u011Bku 6 \u2013 18 let.\n-\tL\u00E9\u010Dba ren\u00E1ln\u00EDho onemocn\u011Bn\u00ED u dosp\u011Bl\u00FDch pacient\u016F s\u00A0hypertenz\u00ED a diabetes mellitus 2. typu s\u00A0protein\u00FAri\u00ED \u2265\u00A00,5 g/den jako sou\u010D\u00E1st antihypertenzn\u00ED l\u00E9\u010Dby.\n-\tL\u00E9\u010Dba chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED (u pacient\u016F \u2265 60 let), kdy\u017E l\u00E9\u010Dba ACE inhibitory ji\u017E d\u00E1le nen\u00ED vhodn\u00E1 z\u00A0d\u016Fvodu inkompatibility, zejm\u00E9na ka\u0161le, \u010Di kontraindikac\u00ED. P\u0159ev\u00E1d\u011Bn\u00ED pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm, kte\u0159\u00ED jsou stabiln\u00ED na ACE inhibitoru, na losartan se nedoporu\u010Duje. \nPacienti by m\u011Bli m\u00EDt ejek\u010Dn\u00ED frakci lev\u00E9 komory \u2264 40% a m\u011Bli by b\u00FDt stabilizov\u00E1ni na l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED.\n-\tSn\u00ED\u017Een\u00ED rizika c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody u dosp\u011Bl\u00FDch hypertonik\u016F s\u00A0hypertrofi\u00ED lev\u00E9 komory dokumentovanou na EKG (viz bod 5.1 Studie LIFE, rasa).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL FLM 30X12,5MG" , "@language" : "cs" } ] }] }